Program
SAP-001
A development code.
Its studies are mostly in Gout, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanton Pharma | 30 open or running | phase 2since Jul 17, 2019 | Oct 18, 2018 | none ahead |
| Shanton Pharma Pte. | 22 open or running | phase 2since Dec 12, 2022 | Dec 12, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2018First study: phase 1 study in GoutNew to Shanton PharmaShanton Pharma · NCT03857165 · 24 enrolled · United States
- Jul 17, 2019Phase 2 study in GoutShanton Pharma · NCT04040816 · 40 enrolled · United States
- Dec 12, 2022Shanton Pharma Pte.'s first study: phase 2 study in GoutNew to Shanton Pharma Pte.Shanton Pharma Pte. · NCT05690204 · 87 enrolled · United States, Puerto Rico
- Aug 24, 2023Phase 1 study in GoutShanton Pharma · NCT06678581 · 70 enrolled · China
- Dec 4, 2024Phase 2 study in GoutShanton Pharma Pte. · NCT06729853 · 32 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06729853Gout · United States | 2 | Active, not recruiting | Shanton Pharma Pte. | Jan 17, 2025 | 32 |
| NCT06678581Gout · China | 1 | Completed | Shanton Pharma | Dec 20, 2023 | 70 |
| NCT05690204Gout · United States, Puerto Rico | 2 | Active, not recruiting | Shanton Pharma Pte. | Jan 2025 | 87 |
| NCT04040816Gout · United States | 2 | Completed | Shanton Pharma | Aug 1, 2020 | 40 |
| NCT03857165Gout · United States | 1 | Completed | Shanton Pharma | Jun 2, 2019 | 24 |
How it is read
Names in the registry
- “SAP-001”, 5 entries
Codes read as this program: SAP001.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.